Title: Crystal Clear: Purity of consumer-level methamphetamine samples and methamphetamine-adulteration of other drugs in Los Angeles, 2023-2025

Authors: Adam J. Koncsol, MPA[a,b]; Caitlin A. Molina, BA, BS[a]; Ruby Romero, BA[a]; Megan Grabill, BA[a,c], Morgan E. Godvin, BA[a]; Jesse Carrizal[d]; Manuel Contreras[d]; Oscar Arellano, BA[d]; Naomi Villanueva, MA[e]; Elham Jalayer, BS[e]; spider davila[f]; Soma Snakeoil[g]; Joshua Smith, BS[h], Charles J. Santamaria, BS[h], Leslie Nuñez, BS[h], Ezinne Okonkwo[i], Siddarth Puri, MD[j]; Joseph R. Friedman, MD, PhD, MPH[k]; Chelsea L. Shover, PhD[a,b]

a) Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
b) Dept. of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States
c) Dept. of Anthropology, College of Social Sciences, University of California, Los Angeles, Los Angeles, CA, United States
d) Homeless Outreach Program's Integrated Care System, Los Angeles, CA, United States
e) Bienestar Human Services, Los Angeles, CA, United States
f) Community Health Project LA, Los Angeles, CA, United States
g) The Sidewalk Project, Los Angeles, CA, United States
h) Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
i) University of California, Los Angeles, Los Angeles, CA, United States
j) San Luis Obispo County Department of Behavioral Health, San Luis Obispo, CA, United States
k) University of California, San Diego, San Diego, CA, United States

*Correspondence to Adam J. Koncsol, koncsol@ucla.edu, 1100 Glendon Ave, Ste, 850, Los Angeles, CA 90024

Abstract

Introduction:

The United States (US) has seen a rise in methamphetamine use disorders and methamphetamine-involved deaths. The US Department of Justice and Drug Enforcement Agency reports that seized wholesale methamphetamine is almost uniformly high purity. However, there is limited information on the concentration of methamphetamine at the consumer level. We leverage data from a community-based drug checking program in Los Angeles to investigate (1) the makeup of the retail illicit methamphetamine market and (2) the extent to which methamphetamine plays a role as an adulterant in other drugs.

Methods:

Anonymous participants accessing a community-based drug checking program voluntarily provided samples of illicit drug products and completed brief interviews at four sites in Los Angeles County, California, from February 2023 to January 2026. Samples underwent laboratory-based qualitative testing via direct analysis in real-time mass spectrometry (DART-MS) and quantitative liquid-chromatography mass spectrometry (LC/MS). We quantitated the presence and concentration of methamphetamine as well as all other identified substances among 1) samples expected only to be methamphetamine and 2) samples expected to be another substance (e.g., fentanyl, heroin) where methamphetamine was found as an adulterant/contaminant.

Results:

Of N=2193 total samples, n=652 (29.7%) were methamphetamine-positive on DART-MS. Among methamphetamine-positive samples, the drug was an expected component in two thirds of samples and unexpected in one third. In samples expected to contain methamphetamine, the mean purity was 78.2% (SD 24.0%; range <1% to ≈100%). As an unexpected component, the mean methamphetamine purity was 17.8% (SD 32.3%), and was mostly commonly found in samples expected to be fentanyl, heroin, MDMA, other amphetamines (e.g., counterfeit Adderall), and 2C-B.

Conclusions:

Consumers in Los Angeles seeking methamphetamine appear to frequently obtain high-purity samples that are rarely adulterated with other substances, although we observed a wide variation in concentration between samples. In contrast, drugs purchased without the expectation of containing methamphetamine had substantively high prevalence of methamphetamine adulteration/contamination. Both intentional and unwitting consumers may be vulnerable to the health risks of potent and variable

65   methamphetamine, including psychiatric, cardiovascular, and other illnesses. Future

66   research should expand methamphetamine surveillance techniques and investigate

67   how variability in illicit markets may impact health outcomes.

Keywords: *drug checking; illicit drug supply; quantitation, harm reduction, surveillance*

Highlights:

- o Samples expected to contain methamphetamine had a mean purity of 72% (SD 24%).

- o For 90% of samples expected to be meth, no other active compounds were detected.

- o Meth was a substantial adulterant in other drugs, e.g. opioids (mean purity 17%).

Introduction:

Methamphetamine is a central nervous system stimulant that carries potential health risks to multiple organ systems and is implicated in a rising number of drug-related deaths [1–5]. Methamphetamine use appears to be increasing around the world, particularly in the Americas, Asia, and Australia [6–9]. Health consequences of methamphetamine use have also increased, with the U.S. seeing a rise in methamphetamine-related deaths from 4,500 in 2015 to approximately 30,000 in 2024 (National Center for Health Statistics, 2025). Chronic methamphetamine use increases the risk of cardiovascular harms such as myocardial toxicity, coronary artery disease, hypertension, stroke, sudden cardiac arrest, and other causes of morbidity and mortality [1–5].

As a fully synthetic drug, methamphetamine is considerably cheaper and easier to produce than agriculturally-derived stimulants like cocaine [10–12]. Methamphetamine seized by law enforcement tends to have exceptionally high purity, with most recently available U.S. national averages exceeding 90% [13–15]. However, drugs seized in criminal investigations are potentially interdicted higher in the supply chain prior to adulteration by lower-level sellers and may reflect purer product than what end-consumers receive. Drug checking—chemically testing personal samples of drugs for harm reduction and supply monitoring—can characterize methamphetamine purity and adulteration at the consumer level.

Los Angeles County, California has long led the United States in both number of methamphetamine-related deaths (reflecting the large population) and proportion of all drug-related deaths attributable to methamphetamine (reflecting a persistent market) [16]. In recent years, an increasing number of Los Angeles County's deaths attributed to methamphetamine were also attributed to fentanyl [16]. This pattern is mirrored in national data, where the fourth wave of the U.S. overdose crisis is characterized by deaths involving polysubstance combinations of fentanyl and other synthetic opioids and stimulants like cocaine [17,18]. While public health campaigns have often focused on the threat of fentanyl adulteration of other drugs, data from testing actual drug products has been limited. Leveraging data from a community-based drug checking program, we sought to empirically investigate the methamphetamine supply in Los Angeles. Specifically, we sought to characterize the presence and purity/concentration of methamphetamine and co-detected substances among 1) methamphetamine-positive samples expected only to be methamphetamine and 2) methamphetamine-positive samples expected to be another substance (e.g., purchased as fentanyl or heroin) where methamphetamine is functioning as an adulterant. "Purity" is used to refer specifically to the percentage by mass of methamphetamine in samples expected to be methamphetamine, whereas "concentration" is used to refer to the percentage by mass

113 of any compound present in any drug (e.g., methamphetamine in a sample expected to
114 be fentanyl).

Methods:

Anonymous participants utilizing a community-based drug checking program,
Drug Checking Los Angeles, voluntarily provided a small sample (approximately 1-5
mg) of drug products (e.g., powders, crystals, pills, liquids, tar, etc.) for testing at four
different sites in Los Angeles County, California: (1) East Los Angeles, (2) Downtown
Los Angeles / Skid Row, (3) Hollywood, and (4) South Los Angeles. This study uses
data collected from February 2023 to December 2025. An optional survey was
administered by trained staff to assess what the drug was purported to be at the time of
sale and what a participant expected the sample to contain. Instances where a
respondent did not know what the sample contained or declined to answer are
presented as "Unknown / Declined."

Initial-point-of-service drug checking used Fourier-Transform Infrared (FTIR)
spectroscopy and various BTNX-branded and lab-validated immunoassay test strips,
such as fentanyl and methamphetamine test strips [19]. Samples received through Drug
Checking Los Angeles were tested in the field to provide real-time results to participants
and also sent by mail to the National Institute of Standards and Technology Rapid Drug
Analysis and Research (NIST RaDAR) program for laboratory-based analysis [20]. NIST
RaDAR evaluated all samples included in the study with direct analysis in real time
mass spectrometry (DART-MS) and a subset of samples with liquid-chromatography
mass spectrometry (LC/MS).

DART-MS methods assess samples against a library of nearly 1,500 substances,
including most pharmaceutical and illicitly manufactured drugs, adulterants, cutting and
bulking agents, precursor chemicals, and other relevant substances (adhesives,
industrial ingredients, etc.). DART-MS methods are only able to provide information on
the binary presence or absence of compounds and are unable to provide information on
concentration; however, they only require residual or trace amounts of a sample to be
analyzed. A subset of samples analyzed with DART-MS were also analyzed with LC/MS
methods to quantitate the percent mass of pre-specified compounds present in the
sample. See **Supplemental Table A** for more information about the specific analytes
used on the LC/MS quantitation panel. More detailed descriptions of the confirmatory
DART-MS and LC/MS methodologies employed in this study have been previously
published [21]. An important limitation to all reported results is that laboratory methods
may be unequipped to detect byproduct or precursor compounds related to the
synthesis products for which laboratory standards do not exist.

Methamphetamine concentration values reported by NIST RaDAR were
expressed as methamphetamine freebase. To account for the molecular weight of the

hydrochloride salt when calculating concentration estimates, methamphetamine
freebase was converted to methamphetamine HCl. Dividing the molecular weight of
methamphetamine HCl (185 Da) by the molecular weight of methamphetamine
freebase (149 Da) and multiplying that conversion factor (approximately 1.24) by each
methamphetamine freebase value can provide a more accurate estimation of
methamphetamine concentration in our sample—especially because all samples of
methamphetamine tested were sold as "crystal methamphetamine" or "ice". As a result
of the freebase-to-salt concentration conversion, any samples ≥85% methamphetamine
freebase were treated as pure and were imputed to be 100% for this analysis. Similarly,
samples that were considered below the limit of quantitation (<LOQ) were imputed to be
0.1% to calculate descriptive statistics.

The count and prevalence (%) of any co-detected compounds were calculated
across methamphetamine-expected and methamphetamine-unexpected samples
confirmed with DART-MS to contain methamphetamine. This highlights (1) compounds
that may be present in samples expected to be methamphetamine and (2) how often
methamphetamine was detected in samples expected to be other drugs, like heroin or
fentanyl. For the subset of samples that underwent quantitative LC/MS analysis, the
concentration was assessed in terms of average, standard deviation, and range of
methamphetamine, presented across participant drug expectation categories. Study
protocols were approved by the UCLA IRB (IRB-22-0760 and IRB-22-1273). FTIR
analyses were completed using OPUS, version 8.7.31 (Bruker, Billerica, MA, USA).
Statistical analyses were carried out using Stata, version 19.5 (StataCorp, College
Station, TX, USA).

Results:

We tested N = 2,193 samples of drug product with DART-MS from February
2023 to December 2025. Among n = 652 samples found to contain methamphetamine,
67% were expected to contain methamphetamine (n = 432 methamphetamine-only, n =
2 methamphetamine + heroin mixture, n = 1 methamphetamine + fentanyl mixture, and
n = 1 methamphetamine + ketamine mixture). The remaining 33% (n=220) were not
expected to contain methamphetamine.

Table 1 shows co-detected substances among n=432 of methamphetamine-
positive samples expected to only contain methamphetamine. The most commonly co-
prevalent compounds were cocaine (n=9, 2.1%), ephedrine (n=8, 1.9%), lidocaine (n=8,
1.9%), and fentanyl (n=7, 1.6%). Most samples (n=387, 89.6%) expected to be
methamphetamine contained only methamphetamine, with no other co-prevalent
compounds detected on DART-MS.

Of the n=652 samples confirmed to contain methamphetamine, a subset (n=208)
underwent LC/MS analysis. For quantitated samples expected to be methamphetamine

(n=172), the average percent by mass of methamphetamine hydrochloride was 78.2%
(SD=24.0%) and ranged from below the limit of quantitation (≈ 0.1%) to virtually pure
(≈100%). **Figure 1** highlights the distribution of methamphetamine concentration among
samples expected to be methamphetamine vs where methamphetamine was not
expected, excluding n=11 samples where the expected drug could not be determined.
For samples which were not pure methamphetamine but did not contain any additional
compounds on DART-MS, the remaining percentage mass of the sample was likely to
be inert precursors and byproducts related to inefficient methamphetamine synthesis.

In approximately 33% (n=220) of samples in which methamphetamine was
detected, its presence was not expected by the participant. **Table 2 and Figure 2**
highlight how frequently methamphetamine was detected as an adulterant in drug
products expected to be other substances. Notably, methamphetamine was detected in
8.5% of expected fentanyl samples (n=62), 16.4% of expected heroin samples (n = 34),
14.0% of expected MDMA / MDA samples (n =19), and 70.4% of expected
amphetamine samples (n =19). It was also detected among samples expected to be 2C-
B (41.2%, n=7), benzodiazepines (11.5%, n = 6), and GHB / BDO (33.3%, n=2). In our
sample, methamphetamine was occasionally detected in samples expected to be
oxycodone (4.0%, n =3), powder and crack cocaine (3.8%, n=6), and was not detected
in the few samples expected to be designer stimulants, cathinones, or research
chemicals others brought for testing. Although we are cautious to extrapolate due to
small sample sizes, these emerging compounds may be ripe for methamphetamine
adulteration given their entactogenic and stimulating effects as well as relatively
significantly higher market prices.

Table 3 displays the concentration of methamphetamine in samples expected to
be methamphetamine, as well as its concentration in other drugs (when it is present as
an adulterant). When present as an adulterant in other drugs, methamphetamine was
present at levels that are likely clinically relevant. For example, among 30 samples
expected to only contain fentanyl, the mean methamphetamine concentration was
17.5% by mass. Similarly, in 9 samples expected to only contain heroin, the average
methamphetamine concentration was 15.2% by mass. Notably, however, was how
heterogeneous methamphetamine adulteration was across samples of heroin and
fentanyl, with standard deviations of methamphetamine concentration being 33.0% and
27.0%, respectively.

Discussion:

In this study of consumer-level methamphetamine-involved samples, we found
that drugs expected to be methamphetamine overwhelmingly—90% of the time—
contained only methamphetamine. In contrast, samples expected to only contain other
drugs (including fentanyl, heroin, MDMA, 2C-B, and others) often unexpectedly

contained methamphetamine. Overall, this reflects the increasingly ubiquitous role of
inexpensive and highly pure methamphetamine in various aspects of the illicit drug
market, as well as the volatility of the drug supply in the age of synthetic drugs more
generally. In our sample, the percentage mass of methamphetamine in a sample
expected to be methamphetamine ranged from well below 1% to nearly 100%, with an
average of 78%. These findings illustrate that the purity of methamphetamine at the
consumer-level in Los Angeles is not as uniform or high as law enforcement seizure
data suggest (95%-100%).

Variation in methamphetamine purity may have implications for the health risks of
individuals exposed to the drug. Individuals expecting or accustomed to lower purity
samples may be inadvertently and unwittingly exposed to a higher dose. This likely has
implications for methamphetamine toxicity, including risk of psychosis, mood
dysregulation, cardiovascular and pulmonary harms. Similarly, understanding variation
in potency may have implications for treatment initiation and retention with medications
for methamphetamine use disorder, as well as psychosocial and behavioral
interventions such as contingency management, cognitive behavioral therapy,
motivational interviewing, and community reinforcement approaches [22–30].
Understanding methamphetamine purity at the consumer level can help more fully
contextualize health-related harms associated with methamphetamine, along with other
factors relevant to clinical care, like the dosage, frequency of use, route of
administration. Additional public health interventions that include harm reduction
programming for people who use methamphetamine may be able to consider that
methamphetamine purity varies significantly between batches when suggesting
methods to avoid 'overamping' and other negative effects of methamphetamine use.

Our findings do not support the notion that fentanyl has been regularly added to
drug products sold as methamphetamine in Los Angeles. Fentanyl was detected in
1.6% of samples expected to be methamphetamine, and in the few cases where
quantitative data were available, the concentrations were very low. It is unknown how
many of these samples were purchased already contaminated versus being later
contaminated by co-use through shared paraphernalia or storage, given that
polysubstance use was commonly reported by drug checking participants. These
findings may not generalize more broadly as drug markets are often highly localized and
may change rapidly.

The balance between high-risk yet low probability of fentanyl adulteration in
methamphetamine can inform measured public health communications. Any fentanyl
cross-contamination, even trace amounts, presents a substantial risk of fatal opioid
overdose to people without opioid tolerance; thus, recommendation to check stimulants
for fentanyl before use remains an important harm reduction strategy. However,
messaging should take care not to imply or assert that methamphetamine adulteration

with fentanyl is widespread. Evidence-based messaging can help promote safer
practices while also maintaining credibility with people who use drugs and their
communities.

Nevertheless, we did find that methamphetamine was regularly detected in
samples expected to be other drugs, mostly fentanyl, heroin, and MDMA, sometimes at
substantial and potentially clinically relevant amounts. For example, one sample of
powder heroin contained 10 times more methamphetamine than heroin by weight: 81%
methamphetamine to only 7% of heroin. **These findings help provide context to the**
role that methamphetamine often can serve in Los Angeles markets: an
adulterant to other substances rather than the target of adulteration itself.
Importantly, people who use drugs such as fentanyl, heroin, MDMA, and other
amphetamines may unknowingly be exposed to methamphetamine, which could have
harmful or unpleasant consequences. When methamphetamine was detected in other
drugs, it was typically detected at levels which may be pharmacologically significant.
Unintentional methamphetamine exposure may contribute to physical health and
psychiatric signs and symptoms inconsistent with the clinical presentation typical of
using opioids or shorter-acting stimulants (such as cocaine or MDMA) alone. Harm
reduction interventions could underscore the risk of methamphetamine adulteration in
other drugs and the potential harms of unintentional exposure. Test strips are one
example of a validated, low-cost, and low-barrier technology that could be leveraged to
help people avoid unwanted exposure to methamphetamine [19].

These findings also help to highlight the potential value of data from community-
based drug checking programs. Given that illicit markets are highly volatile and
constantly shifting, community-based drug checking programs empower people who
use drugs to make decisions in real time while also providing aggregated
epidemiological surveillance of multiple, and sometimes overlapping, drug supplies.

Limitations:

While methamphetamine samples tested through a community-based drug
checking program can provide unique insights into consumer-level drug markets, there
are several limitations to consider. Given the sensitivity of laboratory instruments,
detection of adulterants at low levels could occur due to brief, accidental cross-
contamination—especially in instances where a person reports that they use both
substances. Cross-contamination could also occur through storing multiple drug
products in the same bag, or even by touching one substance and then touching
another. Although polysubstance use and co-storage information was ascertained by
drug checking staff if a participant opted to share that information, it was not possible to
completely distinguish between intentional adulteration and accidental cross-
contamination. The use of quantitative testing, however, helps to contextualize

instances wherein methamphetamine adulteration represents a large portion of the
sample tested—far above levels that would be expected from accidental cross-
contamination alone.

The fallibility of a participant's memory to accurately recall drug expectation may
have also biased our results. Given that drug expectation was ascertained through
participant self-report, a participant may have misremembered or mixed up bags.
Despite our best efforts to sample across four geographically and culturally distinct
areas of Los Angeles, this is ultimately a convenience sample that may or may not be
generalizable to drugs not submitted for checking. For example, a participant may be
more likely to bring a sample to check after an adverse or unusual experience or
because they were already utilizing SSP services. Laboratory methods are subject to
various errors that may affect the precision of our estimates, including the margin of
error in quantification and limitations of specific analytical methods. For example, DART-
MS techniques are not generally equipped to detect some molecules, like lactose or
starches, so the prevalence of some cutting agents, such as lactose, are not reflected in
these results. DART-MS methods may have also missed byproduct or precursor
compounds related to the methamphetamine synthesis process for which laboratory
standards may not yet exist—helping to explain the gap between samples with only
methamphetamine detected yet were below 100% pure methamphetamine
concentration. The LC/MS quantitation panel only included a subset of all potential
compounds, and substances not on this panel were unable to be quantitated. We aimed
to mitigate some of these limitations via the use of multiple technologies, yet results
should be interpreted in light of these potential sources of error and bias.

Conclusion:

Methamphetamine purity in Los Angeles is high on average, however, lower than
the >95% values seen in wholesale seizure data. Few contaminants were detected
among samples expected to be methamphetamine; however, the purity of
methamphetamine in the community setting is highly heterogeneous between samples.
Methamphetamine is frequently used as an adulterant in other drugs—often at
pharmacologically-relevant concentrations (i.e., representing a large fraction of the
sample). Understanding methamphetamine concentration among drug samples in the
community has a number of potential clinical and public health implications. Public
health surveillance of consumer-level drug markets may facilitate interventions to
address population-wide increases in methamphetamine use, shifting purity, and new
adulterants. Future research is needed to evaluate how these findings compare to drug
markets beyond Los Angeles. Further research is warranted to understand
methamphetamine as an adulterant and the health effects of intentional and
unintentional polysubstance use.

Table 1: The count and proportion of prevalent compounds among only-methamphetamine expected and positive samples

	Class	Compound	Methamphetamine-only expected samples	
			Count	Proportion
Qualitative co-prevalent compounds	**Amphetamines**	Methamphetamine	432	100.0%
		N, N Dimethylamphetamine	4	0.9%
		MDAI	3	0.7%
		MDMA	1	0.2%
	Fentanyl, fentalogs, and fentanyl precursors	Fentanyl	7	1.6%
		4-ANPP	1	0.2%
		Aniline	1	0.2%
		Acetyl fentanyl	1	0.2%
	Heroin and related compounds	Heroin	2	0.5%
		6-MAM	1	0.2%
		Papaverine	1	0.2%
		Noscapine	1	0.2%
	Anesthetics	Cocaine	9	2.1%
		Lidocaine	8	1.9%
		Benzocaine	1	0.2%
	Other drugs	Ephedrine	8	1.9%
		Epinephrine / Adrenaline	2	0.5%
		Acetaminophen	1	0.2%
		Ketamine	1	0.2%
	Cutting agents & fillers	Dimethyl Sulfone (MSM)	6	1.4%
		Diethyl Phthalate	2	0.5%
		Levamisole	1	0.2%
		Triacetin	1	0.2%
	Total	N	432	100.0%

Note: Table shows the count and proportion (%) of compounds that were detected among n = 432 methamphetamine-positive samples which were expected to be methamphetamine. Samples collected February 2023 - December 2025 through a community-based drug checking program in Los Angeles.

Table 2: Methamphetamine positivity by drug expectation

Expected drug	Methamphetamine negative		Methamphetamine positive		Total samples	
	Count	*Proportion*	*Count*	*Proportion*	*Count*	*Proportion*
Methamphetamine	9	2.0%	432	98.0%	441	20.1%
Fentanyl	671	91.5%	62	8.5%	733	33.4%
Heroin	173	83.6%	34	16.4%	207	9.4%
Amphetamine	8	29.6%	19	70.4%	27	1.2%
MDMA / XTC	117	86.0%	19	14.0%	136	6.2%
2C-B	10	58.8%	7	41.2%	17	0.8%
Benzodiazepines	46	88.5%	6	11.5%	52	2.4%
Cocaine or Crack	152	96.2%	6	3.8%	158	7.2%
"Psilocybin" products	5	62.5%	3	37.5%	8	0.4%
Oxycodone	72	96.0%	3	4.0%	75	3.4%
Heroin and Methamphetamine mixture	0	0.0%	2	100.0%	2	0.1%
GHB or BDO	4	66.7%	2	33.3%	6	0.3%
Amoxicillin	0	0.0%	1	100.0%	1	0.0%
Cannabis	1	50.0%	1	50.0%	2	0.1%
Dexmethylphenidate	0	0.0%	1	100.0%	1	0.0%
Methamphetamine and Fentanyl mixture	1	50.0%	1	50.0%	2	0.1%
Methamphetamine and Ketamine mixture	0	0.0%	1	100.0%	1	0.0%
Fentanyl and Heroin mixture	4	80.0%	1	20.0%	5	0.2%
PCP	6	85.7%	1	14.3%	7	0.3%

Ketamine	78	98.7%	1	1.3%	79	3.6%
Unknown/declined	122	71.3%	49	28.7%	171	7.8%
Total	1541	70.3%	652	29.7%	2193	100.0%

Note: There were n = 652 samples of drug product that were confirmed positive for methamphetamine and are a subset of N = 2,193 total samples that were brought for testing at a community-based drug checking site in Los Angeles. Samples collected February 2023 - December 2025. DART-MS methods were used to qualitatively assess the presence of methamphetamine. Semi-structured ethnographic interviewing methods were used to capture what participants expected their drugs to be at the time of testing, either through what the substance was bought as or what the participant otherwise expected the sample to contain and may be subject to bias.

Table 3: Methamphetamine appears in other illicit drugs, sometimes in significant quantities

		Average methamphetamine concentration (percent by mass)	Standard Deviation	Range	N
Expected drug or substance	Methamphetamine	78.2	24.0	[<LOQ - ≈100%]	145
	Fentanyl	17.5	33.0	[<LOQ - ≈100%]	30
	Amphetamines	19.5	32.6	[<LOQ - 90.0%]	8
	Heroin	15.2	27.0	[<LOQ - 81.3%]	9
	2C-B	4.9	.	4.9%	1
	Cocaine / crack	49.3	69.6	[<LOQ - 98.6%]	2
	GHB	<LOQ	.	<LOQ	1
	Oxycodone	3.8	.	3.8%	1
	Unknown / Declined	65.9	38.3	[24.8% - ≈100%]	11
	All methamphetamine-positive samples	62.4	37.5	[<LOQ - ≈100.0%]	208

Note: Table shows the methamphetamine concentration (percent by mass), standard deviation, range, count of samples and participant's expected drug or substance among n = 208 methamphetamine-positive, LC-MS quantitated samples. Data collected February 2023 - December 2025 in Los Angeles. Semi-structured ethnographic interviewing methods were used to capture what participants expected their sample to be at the time of testing, either through what the drug or substance was bought as or what the participant otherwise expected the sample to contain. As with other forms of self-reported data, these data may be subject to bias if a

participant mixed up samples or otherwise made an error in recalling what they bought a sample as.

Supplemental table A: LC/MS Quantitation Panel

Class	Quantitative Analyte
Amphetamines	Methamphetamine
Fentanyl, fentalogs, and fentanyl precursors	Fentanyl
	Carfentanil†
	Fluorofentanyl
	4-ANPP
	Ethyl 4-ANPP
	Phenethyl 4-ANPP
α₂- agonists	Xylazine
	Medetomidine
Heroin and related compounds	Heroin
	6-MAM†
	Noscapine†
	Papaverine†
Anesthetics	Cocaine
	Lidocaine*
	Procaine†
	Tetracaine
Other drugs	Acetaminophen
	Caffeine†
	Ketamine
	Levamisole†
	Quetiapine (Seroquel)

Cutting agents & fillers	BTMPS*

*Added to the quantitation panel in July 2024
†Added to the quantitation panel in January 2025

Funding Acknowledgements:

This work was supported by the Centers for Disease Control and Prevention as part of Overdose Data to Action: LOCAL (CDC-RFA-CE-23-0003), National Institutes of Health (R01 DA057630), and an equipment grant from the James B. Pendleton Charitable Trust to the UCLA AIDS Institute and UCLA Center for AIDS Research. AJK was supported by the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI (grant TL1TR001883). CLS was supported by the U.S. National Institute on Drug Abuse (grant K01DA050771). The funders had no role in designing the study, analyzing the data, or the decision to submit for publication.

Additional Acknowledgments:

We would also like to acknowledgment our laboratory partners at the National Institute of Standards and Technology Rapid Drug Analysis and Research program (NIST RaDAR). We would also like to acknowledge our community partners at Bienestar Human Services, Community Health Project LA, The Sidewalk Project, and Homeless Outreach Program's Integrated Care System (HOPICS). We would also like to extend our gratitude to the anonymous participants of Drug Checking Los Angeles who made this work possible through their donation of samples for confirmatory testing.

References

1. Dickson SD, Thomas IC, Bhatia HS, et al. Methamphetamine-Associated Heart Failure
Hospitalizations Across the United States: Geographic and Social Disparities. *J Am Heart*
Assoc. 2021;10(16):e018370. doi:10.1161/JAHA.120.018370

2. Schürer S, Klingel K, Sandri M, et al. Clinical Characteristics, Histopathological Features, and
Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. *JACC Heart Fail*.
2017;5(6):435-445. doi:10.1016/j.jchf.2017.02.017

3. Schwarzbach V, Lenk K, Laufs U. Methamphetamine-related cardiovascular diseases. *ESC*
Heart Fail. 2020;7(2):407-414. doi:10.1002/ehf2.12572

4. Somma V, Osekowski M, Paratz E, Bonomo Y. Methamphetamine-associated
cardiomyopathy: an addiction medicine perspective. *Intern Med J*. 2023;53(1):21-26.
doi:10.1111/imj.15990

5. Tobolski J, Sawyer DB, Song SJ, Afari ME. Cardiovascular disease associated with
methamphetamine use: a review. *Heart Fail Rev*. 2022;27(6):2059-2065.
doi:10.1007/s10741-022-10261-7

6. Blemings B, Cunningham S. Temporary gains and permanent costs in methamphetamine
precursor control. *Int J Drug Policy*. Published online June 2024:104501.
doi:10.1016/j.drugpo.2024.104501

7. Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine Use,
Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. *JAMA*
Psychiatry. 2021;78(12):1329. doi:10.1001/jamapsychiatry.2021.2588

8. Han B, Cotto J, Etz K, Einstein EB, Compton WM, Volkow ND. Methamphetamine Overdose
Deaths in the US by Sex and Race and Ethnicity. *JAMA Psychiatry*. 2021;78(5):564.
doi:10.1001/jamapsychiatry.2020.4321

9. Hedegaard H, Miniño A, Warner M. Drug Overdose Deaths in the United States, 1999–2018.
NCHS Data Brief. 2020;(356).

10. Jones CM, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine
use in the United States: epidemiological update and implications for prevention,
treatment, and harm reduction. *Ann N Y Acad Sci*. 2022;1508(1):3-22.
doi:10.1111/nyas.14688

11. Lewis D, Kenneally M, Van denHeuvel C, Byard RW. Methamphetamine deaths: Changing
trends and diagnostic issues. *Med Sci Law*. 2021;61(2):130-137.
doi:10.1177/0025802420986707

12. Montero F, Bourgois P, Friedman J. Potency-Enhancing Synthetics in the Drug Overdose
Epidemic: Xylazine ("Tranq"), Fentanyl, Methamphetamine, and the Displacement of Heroin
in Philadelphia and Tijuana. *J Illicit Econ Dev*. 2022;4(2):204-222. doi:10.31389/jied.122

13. Drug Enforcement Administration Special Testing and Research Laboratory of the Office of
Forensic Science. *Methamphetamine Profiling Program Report: CY 2022*. 2024.
https://www.dea.gov/sites/default/files/2025-
02/508_CY%202022%20MPP_LS%20Report%20PRB%202024-02.pdf

14. Toske SG, McKibben TD. Monitoring methamphetamine in the United States: A two-decade
review as seen by the DEA methamphetamine profiling program. *Drug Test Anal*.
2022;14(3):416-426. doi:10.1002/dta.3186

15. United States Sentencing Commission. Methamphetamine Trafficking Offenses in the
Federal Criminal Justice System. United States Sentencing Commission. June 10, 2024.
Accessed November 22, 2024. https://www.ussc.gov/sites/default/files/pdf/research-and-
publications/researchpublications/ 2024/202406_Methamphetamine.pdf

16. Shover CL, Friedman JR, Romero R, et al. Longitudinal changes in co-involved drugs,
comorbidities, and demographics of methamphetamine-related deaths in Los Angeles
County. *J Subst Use Addict Treat*. 2023;151. doi:10.1016/j.josat.2023.209101

17. Ciccarone D. The Rise of Illicit Fentanyls, Stimulants and the Fourth Wave of the Opioid
Overdose Crisis. *Curr Opin Psychiatry*. 2021;34(4):344-350.
doi:10.1097/YCO.0000000000000717

18. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and
demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-
2021. *Addict Abingdon Engl*. 2023;118(12):2477-2485. doi:10.1111/add.16318

19. Sisco E, Pyfrom EM, Banta-Green CJ, et al. Beyond fentanyl test strips: investigating other
urine drug test strips for drug checking applications. *Forensic Chem*. 2024;40:100594.
doi:10.1016/j.forc.2024.100594

20. NIST RaDAR. RaDAR Training Materials. NIST. January 1, 2022. Accessed April 15, 2026.
https://www.nist.gov/programs-projects/radar-training-materials

21. Appley MG, Robinson EL, Thomson A, Russell E, Sisco E. An analytical platform for near real-
time drug landscape monitoring using paraphernalia residues. *Forensic Chem*.
2023;34:100489. doi:10.1016/j.forc.2023.100489

22. Ciccarone D, Shoptaw S. Understanding Stimulant Use and Use Disorders in a New Era. *Med
Clin North Am*. 2022;106(1):81-97. doi:10.1016/j.mcna.2021.08.010

23. Coffin PO, Santos GM, Hern J, et al. Effects of Mirtazapine for Methamphetamine Use
Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men. *JAMA*
Psychiatry. 2020;77(3):246-255. doi:10.1001/jamapsychiatry.2019.3655

24. Colfax GN, Santos GM, Das M, et al. Mirtazapine to Reduce Methamphetamine Use: A
Randomized Controlled Trial. *Arch Gen Psychiatry*. 2011;68(11):1168-1175.
doi:10.1001/archgenpsychiatry.2011.124

25. Lake MT, Shoptaw S, Ipser JC, et al. Decision-Making by Patients With Methamphetamine
Use Disorder Receiving Contingency Management Treatment: Magnitude and Frequency
Effects. *Front Psychiatry*. 2020;11. doi:10.3389/fpsyt.2020.00022

26. Li MJ, Shoptaw SJ. Clinical Management of Psychostimulant Withdrawal: Review of the
Evidence. *Addict Abingdon Engl*. 2023;118(4):750-762. doi:10.1111/add.16093

27. Minozzi S, Saulle R, Amato L, Traccis F, Agabio R. Psychosocial interventions for stimulant use
disorder. *Cochrane Database Syst Rev*. 2024;2024(2):CD011866.
doi:10.1002/14651858.CD011866.pub3

28. Rush CR, Santos GM, McMahan VM, et al. Mirtazapine reduces hypothetical
methamphetamine demand in humans. *Drug Alcohol Depend*. 2025;274:112769.
doi:10.1016/j.drugalcdep.2025.112769

29. Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use
Disorder. *N Engl J Med*. 2021;384(2):140-153. doi:10.1056/NEJMoa2020214

30. Wang G, Smith L, Volkow N, et al. Decreased dopamine activity predicts relapse in
methamphetamine abusers. *Mol Psychiatry*. 2012;17(9):918-925. doi:10.1038/mp.2011.86

Fig. 1. Methamphetamine concentration among samples
(a) expected to methamphetamine or (b) another expected drug

(a) Methamphetamine-only expected (n = 145)

(b) Another drug or mixture expected (n = 52)

μ = 78.2%

μ = 17.8%

Proportion of samples (%)

Methamphetamine HCl concentration (percent mass)

Note: Graph shows distribution of methamphetamine concentration among samples expected to be methamphetamine and samples expected to be another drug or mixture (unknown expectation excluded). N= 197 methamphetamine-positive LCMS-quantitated samples collected Feb. 2023 - Dec. 2025.

Fig 2. Prevalence of Methamphetamine Detection Across Expected Drug Categories

Note: Graph shows methamphetamine positivity among different expected drugs. Bar percentages represent the proportion of samples positive for methamphetamine relative to all samples, per category. N = 2,193 total samples of drug product analyzed, with methamphetamine detected in n = 652. Data collected February 2023 - December 2025 in Los Angeles.